research Alopecia Areata: A tissue specific autoimmune disease of the hair follicle
Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.
Search
forProducts matching "alpecin c1"
Tracking 2 products like 318 Alpecin C1 Caffeine Shampoo and 318 Alpecin C1 Caffeine Shampoo from by companies like Amazon and oxfordon line pharmacy. View all 2 products »
Sort by
Research
870-900 / 1000+ results research 1394 Long non-coding RNA AL136131.3 inhibits hair growth through mediating glycolysis in androgenetic alopecia
AL136131.3 slows hair growth by affecting energy processes in hair loss.
research FC054 The liver monoxygenase system in patients with alopecia
Alopecia patients have a less active liver monoxygenase system, which can be treated with photochemotherapy and system inducers.
research Increased risk of vitamin D deficiency and insufficiency in Black patients with central centrifugal cicatricial alopecia
Black patients with a specific type of hair loss have a much higher chance of lacking enough vitamin D.
research Pilose antler extracts promotes hair growth in androgenetic alopecia mice by activating hair follicle stem cells via the AKT and Wnt pathways
Pilose antler extracts help hair growth by activating hair follicle stem cells.
research Pathogenesis of Alopecia Areata in C3H/HeJ Mice and DEBR Rats
Alopecia areata is an autoimmune disease that targets hair follicles.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.
research Alopecie acquisite
Acquired alopecia is hair loss that can be reversible or irreversible, depending on whether the hair follicle is destroyed.
research Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research 264 CCR5 blockade shows prevention of alopecia areata development as well as improvement of alopecia areata
Blocking CCR5 can prevent and improve hair loss in alopecia areata.
research The Pathogenesis of Primary Cicatricial Alopecias
The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.
research Activity and Safety of Cinchonine Nanostructured Lipid Carriers as a Hair Growth Stimulant in Mice Model of Androgenetic Alopecia
Cinchonine Nanostructured Lipid Carriers serum safely and effectively stimulates hair growth and increases the number and size of hair follicles.
research Synergistic treatment of androgenetic alopecia with follicular co-delivery of minoxidil and cedrol in metal-organic frameworks stabilized by covalently cross-linked cyclodextrins
A new hair loss treatment combining minoxidil and cedrol improves hair growth and reduces side effects.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research TRICHOLOGY FEATURES OF ALOPECIA IN WOMEN OF REPRODUCTIVE AGE PATIENTS WITH POLYCYSTIC OVARY SYNDROM
Women of reproductive age with polycystic ovary syndrome often experience hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research RAPID ALKALINIZATION FACTOR 22 is a key modulator of the root hair growth responses to fungal ethylene emissions in Arabidopsis
RALF22 is essential for root hair growth in response to fungal emissions in Arabidopsis.
research CLINICAL ASSESSMENT OF THE THERAPEUTIC OPTIONS FOR ALOPECIA TREATMENT
Different hair loss treatments like topical mixtures, plasma infiltrations, and oral medicine can stop hair loss and improve hair density and follicle size.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research 0953 Double knockdown of DKK1 and SFRP1, two key players in androgenetic alopecia, does not accelerate the hair-growth promoting effect of individual SFRP1 knockdown in healthy human hair follicles ex vivo
research Sticking It to Alopecia
Triamcinolone acetonide injections help regrow hair in alopecia areata patients.
research In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells
Araliadiol may promote hair growth like minoxidil without being toxic.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
research ALOPECIA AREATA
Alopecia areata's causes are unclear, treatments exist but relapses are common.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results
Both mouse and rat models are effective for testing alopecia areata treatments.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.